NR4A1 and breast carcinoma: ErbB2-positive subtype, together with the hormone receptor-positive/ErbB2-negative and triple-negative subtypes, represents the major molecular classification of breast cancer patients that guides the selection of therapeutic strategies in the clinical treatment [36].